Literature DB >> 17989120

Interleukin-18 production and pulmonary function in COPD.

H Imaoka1, T Hoshino, S Takei, T Kinoshita, M Okamoto, T Kawayama, S Kato, H Iwasaki, K Watanabe, H Aizawa.   

Abstract

Interleukin (IL)-18 production and pulmonary function were evaluated in patients with chronic obstructive pulmonary disease (COPD) in order to determine the role of IL-18 in COPD. Immunohistochemical techniques were used to examine IL-18 production in the lungs of patients with very severe COPD (Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage IV, n = 16), smokers (n = 27) and nonsmokers (n = 23). Serum cytokine levels and pulmonary function were analysed in patients with GOLD stage I-IV COPD (n = 62), smokers (n = 34) and nonsmokers (n = 47). Persistent and severe small airway inflammation was observed in the lungs of ex-smokers with very severe COPD. IL-18 proteins were strongly expressed in alveolar macrophages, CD8+ T-cells, and both the bronchiolar and alveolar epithelia in the lungs of COPD patients. Serum levels of IL-18 in COPD patients and smokers were significantly higher than those in nonsmokers. Moreover, serum levels of IL-18 in patients with GOLD stage III and IV COPD were significantly higher than in smokers and nonsmokers. There was a significant negative correlation between serum IL-18 level and the predicted forced expiratory volume in one second in patients with COPD. In contrast, serum levels of IL-4, IL-13 and interferon-gamma were not significantly increased in any of the three groups. In conclusion, overproduction of interleukin-18 in the lungs may be involved in the pathogenesis of chronic obstructive pulmonary disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17989120     DOI: 10.1183/09031936.00019207

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  48 in total

1.  Interleukin-18: the master regulator driving destructive and remodeling processes in the lungs of patients with chronic obstructive pulmonary disease?

Authors:  Takahiro Nakajima; Caroline A Owen
Journal:  Am J Respir Crit Care Med       Date:  2012-06-01       Impact factor: 21.405

2.  NLRP3 Inflammasome Involves in the Acute Exacerbation of Patients with Chronic Obstructive Pulmonary Disease.

Authors:  Huaying Wang; Chun'er Lv; Shi Wang; Huajuan Ying; Yuesong Weng; Wanjun Yu
Journal:  Inflammation       Date:  2018-08       Impact factor: 4.092

3.  IL-18 induces emphysema and airway and vascular remodeling via IFN-γ, IL-17A, and IL-13.

Authors:  Min-Jong Kang; Je-Min Choi; Bo Hye Kim; Chang-Min Lee; Won-Kyung Cho; Gina Choe; Do-Hyun Kim; Chun Geun Lee; Jack A Elias
Journal:  Am J Respir Crit Care Med       Date:  2012-03-01       Impact factor: 21.405

Review 4.  Synergy of Interleukin (IL)-5 and IL-18 in eosinophil mediated pathogenesis of allergic diseases.

Authors:  Hemanth Kumar Kandikattu; Sathisha Upparahalli Venkateshaiah; Anil Mishra
Journal:  Cytokine Growth Factor Rev       Date:  2019-05-10       Impact factor: 7.638

5.  Cytotoxic potential of lung CD8(+) T cells increases with chronic obstructive pulmonary disease severity and with in vitro stimulation by IL-18 or IL-15.

Authors:  Christine M Freeman; MeiLan K Han; Fernando J Martinez; Susan Murray; Lyrica X Liu; Stephen W Chensue; Timothy J Polak; Joanne Sonstein; Jill C Todt; Theresa M Ames; Douglas A Arenberg; Catherine A Meldrum; Christi Getty; Lisa McCloskey; Jeffrey L Curtis
Journal:  J Immunol       Date:  2010-04-28       Impact factor: 5.422

6.  NLRP3 inflammasome is essential for the development of chronic obstructive pulmonary disease.

Authors:  Wenlin Yang; Hongyan Ni; Haifeng Wang; Huiling Gu
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

Review 7.  The amount of cytokine-release defines different shades of Sars-Cov2 infection.

Authors:  S Bindoli; M Felicetti; P Sfriso; A Doria
Journal:  Exp Biol Med (Maywood)       Date:  2020-05-28

Review 8.  The cytokine network in asthma and chronic obstructive pulmonary disease.

Authors:  Peter J Barnes
Journal:  J Clin Invest       Date:  2008-11       Impact factor: 14.808

Review 9.  Systems biology coupled with label-free high-throughput detection as a novel approach for diagnosis of chronic obstructive pulmonary disease.

Authors:  Joanna L Richens; Richard A Urbanowicz; Elizabeth A M Lunt; Rebecca Metcalf; Jonathan Corne; Lucy Fairclough; Paul O'Shea
Journal:  Respir Res       Date:  2009-04-22

Review 10.  Interleukin-13: prospects for new treatments.

Authors:  C E Brightling; S Saha; F Hollins
Journal:  Clin Exp Allergy       Date:  2009-10-30       Impact factor: 5.018

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.